The World Health Organisation has published new development targets for longer-acting tuberculosis injections, setting out what future medicines would need to achieve before they could be useful in routine care.
The work does not introduce a new treatment and does not mean that an injectable option is ready for patients. Instead, it gives medicine developers and researchers a detailed framework for work that is still at an early stage. Several potential long-acting injectable options for tuberculosis are entering or approaching clinical development, but they will still need to be studied and assessed before any could be used in health services.
Tuberculosis prevention and treatment commonly rely on oral medicines taken every day for months. Keeping to that schedule can be difficult, particularly where treatment is lengthy or where people face practical barriers to regular care. A medicine that remains active in the body for longer could reduce the number of dosing occasions, but that potential benefit depends on the treatment being safe, effective and possible to deliver fairly.
Targets for prevention and disease treatment
The new profiles distinguish between preventive treatment and treatment for tuberculosis disease. For preventive treatment, the desired goal is a complete course delivered through one injection at a single appointment. For tuberculosis disease, the target is a regimen lasting no more than four months and requiring three or fewer dosing appointments.
Those are development targets, not promises about the medicines that will eventually reach the clinic. The profiles set a minimum threshold that a product would need to meet for further work to be worthwhile, alongside a more ambitious target described as desirable but realistically achievable. This approach is intended to help developers weigh difficult choices before major trials or investment decisions are made.
The practical details are central to the framework. Future injections should be capable of being given by a trained health worker at the lowest feasible level of the health system. The profiles also favour small injection volumes and treatments that do not need a cold chain. Any new option would need safety and effectiveness at least comparable with current oral regimens.
Looking beyond the injection itself
The framework also addresses matters that can decide whether a new medicine is genuinely useful outside a research setting. These include trial design, the overall burden of treatment, the ability to scale up delivery, equitable access, transparent pricing and cost. An injection given less often may still be hard to use if it requires specialist facilities, cannot be stored locally or creates a new barrier for people seeking care.
That wider view matters because reducing the number of doses does not automatically reduce the work involved in treatment. Health services would need trained staff, reliable supply arrangements and ways to support people who need follow-up. A less frequent schedule may be meaningful for some people, but it would have to fit within the realities of local services.
The profiles were developed with input spanning clinical research, pharmacology, regulation, national tuberculosis programmes, people with experience of tuberculosis and civil-society representatives. The process also drew on consultation, surveys, focus groups and a multi-country study of treatment preferences. That is reflected in the emphasis on patient choice as well as on laboratory and delivery requirements.
Oral treatment remains part of the picture
Longer-acting injections are not presented as a replacement for every oral option. Work on improved oral regimens is expected to continue, and future services would need to preserve a choice for people who do not want injections or for whom they are not suitable.
The immediate significance is therefore a clearer shared benchmark for a field that remains in development. It sets out what a potential long-acting option would need to offer before it can make a practical difference, while keeping the standard focused on effectiveness, safety, affordability and personal choice. Whether future candidates can meet those standards will depend on the results of research and the decisions that follow.
